Investigational drug · Phase 2
RMC-9805
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for PDAC, Colorectal Cancer, CRC.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "RMC-9805"
First trial start
2024
Jan 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RMC-9805", any sponsor or status.
Conditions studied
As listed on its trial records.
- PDAC
- Colorectal Cancer
- CRC
- Pancreatic Ductal Adenocarcinoma
- Gastrointestinal Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
- Non-Small Cell Lung Cancer, NSCLC
- KRAS, NRAS, HRAS-mutated NSCLC
- KRAS G12C-mutated Solid Tumors, Lung Cancer
- Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "RMC-9805" as an intervention, largest first.
Revolution Medicines, Inc.Industry
NCT06445062 · 1,130 participants (planned) · Start May 24, 2024 · Primary completion Sep 30, 2028
Drug: RMC-6236; mFOLFOX6 regimen and 7 more · For: Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma and 3 more
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 32 sites in all
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )Pivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07621718 · 670 participants (planned) · Start May 22, 2026 · Primary completion Dec 30, 2028
Drug: Zoldonrasib; Placebo and 6 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Tucson, Arizona; New Haven, Connecticut · 25 sites in all
Revolution Medicines, Inc.Industry
NCT06162221 · 616 participants (planned) · Start Jan 18, 2024 · Primary completion Jun 2027
Drug: RMC-6291; RMC-6236 and 5 more · For: Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer and 2 more
Sites: Gilbert, Arizona; Duarte, California; Irvine, California · 98 sites in all
Revolution Medicines, Inc.Industry
NCT06040541 · 604 participants (planned) · Start Sep 7, 2023 · Primary completion Dec 31, 2026
Drug: RMC-9805; RMC-6236 · For: Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC) and 1 more
Sites: Sacramento, California; New Haven, Connecticut; Sarasota, Florida · 17 sites in all
- Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07777822 · 430 participants (planned) · Start Aug 14, 2026 · Primary completion Oct 2029
Drug: zoldonrasib; Placebo and 2 more · For: NSCLC; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer NSCLC and 4 more
Sites: Anchorage, Alaska; Fort Lauderdale, Florida; Plantation, Florida · 4 sites in all
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07805954 · 400 participants (planned) · Start Aug 28, 2026 · Primary completion Mar 2029
Drug: daraxonrasib; gemcitabine and 2 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Jacksonville, Florida · 6 sites in all
Tango Therapeutics, Inc.Industry
NCT06922591 · 183 participants (planned) · Start May 31, 2025 · Primary completion Jun 2027
Drug: TNG462; RMC-9805 and 3 more · For: PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC and 5 more
Sites: Scottsdale, Arizona; Denver, Colorado; Washington D.C., District of Columbia · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Simultaneous LC-MS/MS quantification of four KRAS inhibitors (RMC-6236, RMC-9805, RMC-7977, and MRTX1133) in human plasma: toward therapeutic drug monitoring in pancreatic ductal adenocarcinoma.
Sabbioni G · Bioanalysis 2026
- Saturation mutagenesis library screening identifies on-target secondary resistance mutations in KRASG12D-selective inhibitors.
Xie H, Wang G, Yuan Z, et al. · Cancer Lett 2026
- Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines.
Stickler S, Eggerstorfer MT, Rieche M, et al. · Transl Lung Cancer Res 2026
- Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.
Chatterjee S, Arya S, Sharma N, et al. · Med Oncol 2026
- Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.
Sagawa T, Hirakawa M, Nagashima H, et al. · J Gastrointest Cancer 2026
- Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies.
Jeon E, Song J, Sim T · Future Med Chem 2026
Also in development for PDAC
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- RNK08954Phase 23 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor Cancer, PDAC, KRAS G12D Mutations
- TNG462Phase 23 trials
Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.